150 related articles for article (PubMed ID: 19474823)
1. Mineral metabolism: Should cinacalcet be used in patients who are not on dialysis?
Cannata-Andía JB; Fernández-Martín JL
Nat Rev Nephrol; 2009 Jun; 5(6):307-8. PubMed ID: 19474823
[TBL] [Abstract][Full Text] [Related]
2. Is it worth correcting hyperparathyroidism if hyperphosphatemia and hypocalcemia worsen? A cinacalcet story.
Kalantar-Zadeh K; Kovesdy CP
Am J Kidney Dis; 2009 Feb; 53(2):183-8. PubMed ID: 19166796
[No Abstract] [Full Text] [Related]
3. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.
; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Goodman WG; Herzog CA; Kubo Y; London GM; Mahaffey KW; Mix TC; Moe SM; Trotman ML; Wheeler DC; Parfrey PS
N Engl J Med; 2012 Dec; 367(26):2482-94. PubMed ID: 23121374
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
[TBL] [Abstract][Full Text] [Related]
5. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
Bucharles SGE; Barreto FC; Riella MC
J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
[TBL] [Abstract][Full Text] [Related]
6. Middle-term use of Cinacalcet in paediatric dialysis patients.
Platt C; Inward C; McGraw M; Dudley J; Tizard J; Burren C; Saleem MA
Pediatr Nephrol; 2010 Jan; 25(1):143-8. PubMed ID: 19838738
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006.
St Peter WL; Li Q; Liu J; Persky M; Nieman K; Arko C; Block GA
Clin J Am Soc Nephrol; 2009 Feb; 4(2):354-60. PubMed ID: 19129318
[TBL] [Abstract][Full Text] [Related]
8. Use of cinacalcet in a patient on long-term dialysis with end-stage renal failure and refractory secondary hyperparathyroidism.
Dorsch O
Nephrol Dial Transplant; 2007 Feb; 22(2):637-40. PubMed ID: 17095580
[No Abstract] [Full Text] [Related]
9. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
10. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
[TBL] [Abstract][Full Text] [Related]
11. Cinacalcet hydrochloride in chronic kidney disease-mineral bone disorder.
Yokoyama K
Clin J Am Soc Nephrol; 2009 Sep; 4(9):1405-8. PubMed ID: 19696214
[No Abstract] [Full Text] [Related]
12. Cinacalcet cost and utility in dialysis patients.
Cohen E; Uribarri J
Semin Dial; 2005; 18(4):353-4. PubMed ID: 16076364
[No Abstract] [Full Text] [Related]
13. Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study.
Evenepoel P; Sprangers B; Lerut E; Bammens B; Claes K; Kuypers D; Meijers B; Vanrenterghem Y
Clin Transplant; 2012; 26(3):393-402. PubMed ID: 22007637
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
Dong BJ
Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D
Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
[TBL] [Abstract][Full Text] [Related]
16. Cinacalcet improves control of secondary hyperparathyroidism in peritoneal dialysis: a multicenter study.
Portolés J; López-Sánchez P; Bajo MA; Castellano I; del Peso G; Rodríguez JR; Ribera M; Ortigosa A; Selgas R
Perit Dial Int; 2012; 32(2):208-11. PubMed ID: 22383721
[No Abstract] [Full Text] [Related]
17. [Calcimimetic drugs in stage 3-5 chronic kidney disease].
Grzegorzewska AE; Niepolski L
Pol Merkur Lekarski; 2012 Apr; 32(190):260-2. PubMed ID: 22708286
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological and clinical profiles of calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients on dialysis (cinacalcet hydrochloride, REGPARA)].
Nagano N; Kawata T; Wada M
Nihon Yakurigaku Zasshi; 2008 Nov; 132(5):301-8. PubMed ID: 19008642
[No Abstract] [Full Text] [Related]
19. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Mealing S; Roome C; Snaith A; D'Souza R; Welch K; Stein K
Health Technol Assess; 2007 May; 11(18):iii, xi-xiii, 1-167. PubMed ID: 17462168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
